Aurobindo Pharma has received tentative approval from the US health regulator USFDA for its generic Lacosamide tablets used in treatment of partial seizures in epilepsy patients. The approval has come for Lacosamide tablets in the strengths of 50 mg, 100 mg, 150 mg and 200 mg for its Abbreviated New Drug Application (ANDA). The product is generic equivalent of USB Inc’s Vimpat tablets and is used in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older
Company Profile : Aurobindo Pharma Ltd
Leave a Reply